Search results
Bristol Myers' profit beats on better-than-feared Revlimid sales
Reuters via Yahoo Finance· 1 year ago(Reuters) -Bristol Myers Squibb Co on Thursday reported quarterly earnings that beat analysts'...
Bristol Myers sales fall, cuts 2023 forecast as drugs face competition
Reuters via Yahoo News· 10 months ago(Reuters) -Bristol Myers Squibb on Thursday said its second-quarter sales fell more than expected...
Bristol Myers profit beats estimates on resilient Revlimid sales
Reuters via Yahoo Finance· 2 years ago(Reuters) -Bristol Myers Squibb Co on Wednesday reported bigger second-quarter profit than expected...
Bristol Myers Q3 sales fall on Revlimid, forex pressure
Reuters via Yahoo Finance· 2 years agoSales and earnings in the quarter were still better than expected as sales of Revlimid did not drop...
Bristol Myers Squibb Proved in Q3 Why Its Diverse Portfolio Makes It a Solid Investment
Motley Fool· 6 months agoBristol Myers Squibb (NYSE: BMY) is one of the largest healthcare companies in the world. The...
Bristol-Myers (BMY) Q3 Earnings Beat, Sales Decline Y/Y
Zacks via Yahoo Finance· 2 years agoBristol-Myers Squibb Company BMY reported decent results for the third quarter of 2022. The company...
Bristol-Myers (BMY) Q2 Earnings, Sales Beat on Eliquis, Opdivo
Zacks via Yahoo Finance· 2 years agoBristol-Myers (BMY) earnings and sales beat estimates in the second quarter of 2022 on the back of...
Is Bristol Myers Squibb Stock a Buy Now?
Motley Fool via Yahoo Finance· 4 months agoIt's not exactly fun to be one of Bristol Myers Squibb's (NYSE: BMY) shareholders right now. The company's stock dropped by 31% in the past year, some of...
A Patent Cliff Is Coming For Bristol Myers — Can Billions In New Products Fill The Gap?
Investor's Business Daily· 1 year agoIt's a new day at Bristol Myers Squibb, according to a company executive. But BMY stock remains...
Will New Drugs Help Bristol Myers (BMY) Combat Generic Pressure?
Zacks via Yahoo Finance· 2 years agoBiotech bigwig Bristol Myers BMY has had a decent run this year despite one of its top drugs...
